Drug Profile
AZD 8601
Alternative Names: AZD-8601Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca; Moderna Therapeutics
- Developer AstraZeneca; Moderna Therapeutics; The Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre
- Class Cardiovascular therapies; RNA
- Mechanism of Action Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure
- No development reported Metabolic disorders; Type 2 diabetes mellitus
- Discontinued Cardiovascular disorders
Most Recent Events
- 30 Jun 2022 Discontinued - Preclinical for Cardiovascular disorders in USA (Intracardiac) by June 2022 (AstraZeneca website, August 2022)
- 08 Feb 2022 AstraZeneca terminates the EPICCURE phase IIa trial in Heart failure patients undergoing coronary artery bypass grafting (CABG) surgery [Intracardiac, Injection] in Finland, Germany, and Netherlands (EudraCT2017-002690-19) (NCT03370887)
- 15 Nov 2021 Efficacy and adverse events data from the phase IIa EPICCURE in Heart failure presented at the American Heart Association’s Scientific Sessions annual meeting (AHA-2021)